EUVIMEDEUVIMED entdecken
Open Access

Aptamer-, heparin- or cocktail-based inhibition of S1-ACE2 protein complexes

E Giroux, A Oake, T Lewis, S Martic

Analytical Biochemistry · 2023

DOI: 10.1016/j.ab.2023.115223 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Analytical Biochemistry, 2023. Verfasst von E Giroux und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Forensic Science, Trent University, Peterborough, Canada. Hauptthemen laut MEDLINE: Angiotensin-Converting Enzyme 2, Heparin, SARS-CoV-2. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Natural Sciences and Engineering Research Council of Canada.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The Spike protein (S1) from the Severe acute respiratory syndrome 2 virus binds to angiotensin converting enzyme 2 (ACE2) receptor to initiate infection. Hence, antiviral therapeutic targeting the S1-ACE2 interface is of interest. Herein, we compare the inhibition efficacy of an aptamer to heparin or their cocktail, against wild-type (WT), Omicron, Delta, and Lambda S1-ACE2 complexes. The aptamer-protein complexes had the dissociation constant KD values in the 2-13 nM range. The aptamer half-maximal inhibitory concentration against WT S1-ACE was 17 nM, with the % inhibition in the 12-35% range. Several aptamer-S1 protein complexes were also stable at low pH with 60% inhibition. Despite the similarity in S1 sequences, the extent of inhibition (2-27%) with heparin was highly dependent on the type of S1 protein. More importantly, heparin did not inhibit the WT S1-ACE2 complex but was effective with mutants. The aptamer-heparin cocktail was less effective compared to aptamer or heparin, individually. Modelling data show that either a direct or proximal binding to RBD sites by aptamer or heparin prevents the ACE2 binding. Overall, heparin was as an effective inhibitor as aptamer against certain variants, and represents the more cost-effective neutralizing agent against emerging coronaviruses.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Angiotensin-Converting Enzyme 2HeparinSARS-CoV-2Antiviral AgentsCOVID-19 Drug TreatmentOligonucleotidesProtein BindingSpike Glycoprotein, Coronavirus

Substanzen

Angiotensin-Converting Enzyme 2Antiviral AgentsHeparinOligonucleotidesspike protein, SARS-CoV-2Spike Glycoprotein, Coronavirus

Autor:innen und Institutionen

  • Department of Forensic Science, Trent University, Peterborough, Canada.
  • Flemming College, Peterborough, Canada.
  • Environmental and Life Science Program, Trent University, Peterborough, Canada.
  • Department of Forensic Science, Trent University, Peterborough, Canada; Environmental and Life Science Program, Trent University, Peterborough, Canada. Electronic address: sanelamartic@trentu.ca.

Förderung

  • Natural Sciences and Engineering Research Council of Canada

Zitieren

APA

Giroux, E., Oake, A., Lewis, T., & Martic, S. (2023). Aptamer-, heparin- or cocktail-based inhibition of S1-ACE2 protein complexes. Analytical Biochemistry. https://doi.org/10.1016/j.ab.2023.115223

Vancouver

Giroux E, Oake A, Lewis T, Martic S. Aptamer-, heparin- or cocktail-based inhibition of S1-ACE2 protein complexes. Analytical Biochemistry. 2023. doi:10.1016/j.ab.2023.115223

BibTeX
@article{Giroux2023,
  author = {Giroux, E and Oake, A and Lewis, T and Martic, S},
  title = {Aptamer-, heparin- or cocktail-based inhibition of S1-ACE2 protein complexes},
  journal = {Analytical Biochemistry},
  year = {2023},
  doi = {10.1016/j.ab.2023.115223}
}
Kostenlos starten →